Suchergebnisse - "Eriksson, Marie"

PubPharm (5)

1

Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer : A Randomized, Phase III SPCG-13 Study

enthalten in: Anticancer research | 2022

von Lehtonen, M. | Sormunen, J. | Hjälm-Eriksson, M. | +5

2

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

enthalten in: European urology | 2019

von Kellokumpu-Lehtinen, P. | Hjälm-Eriksson, M. | Thellenberg-Karlsson, C. | +8

ErratumIn: Eur Urol. 2020 Dec;78(6):e241-e242. - PMID 32893063

3

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer : A Randomized Phase III Trial-FIRSTANA

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Oudard, S. | Fizazi, K. | Sengeløv, L. | +13

CommentIn: J Clin Oncol. 2017 Oct 1;35(28):3175-3177. - PMID 28809609

4

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer : a preplanned safety report of the SPCG-13 trial

enthalten in: Prostate cancer and prostatic diseases | 2012

von Kellokumpu-Lehtinen, P. | Hjälm-Eriksson, M. | Thellenberg-Karlsson, C. | +20

5

Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid

enthalten in: Acta oncologica (Stockholm, Sweden) | 2005

von Ullén, A. | Lennartsson, L. | Harmenberg, U. | +4

1
[1]